-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Biogen, Raises Price Target to $260

Benzinga·04/30/2026 15:50:27
Listen to the news
Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $246 to $260.